Highlights from the 2022 Texas MPN Workshop: advances in MPN treatment

Myeloproliferative neoplasms (MPNs) represent a group of rare and heterogeneous diseases which remain a challenge to treat. Several advances have been made in recent years, both in the diagnosis and treatment of MPNs. The 2022 Annual Texas MPN Workshop brought together leading experts in the field, who discussed current and future treatment strategies, ongoing clinical trials, and future outlooks.  In this exclusive podcast, leading experts Ruben Mesa, MD, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, and Naveen Pemmaraju, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, share key updates in the treatment and management of essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF), and more highlights from this year's meeting.